Compare Neurocrine Biosciences Inc (NBIX) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Impinj Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Impinj Inc trades at $165.2 (market cap $5.26B). The key difference: Neurocrine Biosciences Inc is far larger — about 3× Impinj Inc's market cap. Which is the better fit depends on your goals.
| NBIX | PI | |
|---|---|---|
Market Cap | $15.77B | $5.26B |
Sector | Health | Technology |
52-Week High | $185.50 | $241.91 |
52-Week Low | $123.10 | $91.34 |
Enterprise Value | $15.78B | $5.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Impinj (PI) trades at $171.90, down 0.27% on the day, with strong technical momentum indicated by bullish moving averages and recent golden cross formation. The company reported record Q2 2026 revenue and earnings beats, though maintains negative net income margins. Analyst consensus remains strongly bullish with 73% buy ratings and a $194.50 price target representing 13% upside potential from current levels.
While Impinj shows promising revenue growth and technical strength, investors face risks from negative profitability metrics and high valuation multiples. The company's specialized RAIN RFID technology positions it for logistics market expansion, but execution risks and competitive pressures require careful monitoring. Institutional buying activity suggests confidence in long-term prospects despite recent insider selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
